Patent · US Active

Compounds

US9862706B2 · kind B2 · utility

0Cited by
0References
11Claims
0Family size

Assignee

Inventors

Key dates

Filing dateMay 26, 2017
Grant dateJan 9, 2018
Priority date
Expiry dateMay 26, 2037

Classification

  • Technology area (CPC C)Chemistry; Metallurgy
  • CPC primaryC07D233/86
  • WIPO fieldOrganic fine chemistry
  • WIPO sectorChemistry

Abstract

Imidazolone and pyrazolone derivatives of formula (I) described herein exhibit human neutrophil elastase inhibitory properties and are useful for the therapy of diseases and conditions in which HNE is implicated.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.